Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 2/20 | 0.75 |
| ▸ | GLA | P06280 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vadimezan SCHEMBL29356696 | 0.86 | STING1 (1.00) | STING1GLAMEN1KMT2AKDM4E | |
| Vadimezan SCHEMBL29363732 | 0.86 | STING1 (1.00) | STING1GLAMEN1KMT2AKDM4E | |
| Vadimezan SCHEMBL111183 | 0.86 | STING1 (1.00) | STING1GLAMEN1KMT2AKDM4E | |
| SCHEMBL20763280 | 0.85 | STING1 (0.72) | STING1GLAMEN1KMT2AKDM4E | |
| SCHEMBL20762991 | 0.85 | STING1 (0.79) | STING1GLAMEN1KMT2AKDM4E | |
| Vadimezan SCHEMBL4282930 | 0.85 | STING1 (0.97) | STING1GLAMEN1KMT2AKDM4E | |
| Vadimezan SCHEMBL4282923 | 0.85 | STING1 (0.97) | STING1GLAMEN1KMT2AKDM4E | |
| SCHEMBL20762998 | 0.84 | STING1 (0.77) | STING1GLAMEN1KMT2AKDM4E | |
| SCHEMBL20762931 | 0.82 | STING1 (0.75) | STING1GLAMEN1KMT2AKDM4E | |
| SCHEMBL9381286 | 0.81 | STING1 (0.78) | STING1GLAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062377-A1 | ANTI-CANCER COMBINATIONS | CANCER RESEARCH TECHNOLOGY LIMITED | 2009-03-05 | — | — | US | disclosed |
| US-7462642-B2 | Anti-cancer combinations | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-12-09 | — | — | US | disclosed |
| US-20050131059-A1 | Synergistic mixture of 5,6-dimethylxanthenone and diclofenac | CANCER RESEARCH TECHNOLOGY LIMITED | 2005-06-16 | — | — | US | disclosed |
| EP-1487433-A1 | ANTI-CANCER COMBINATIONS OF DMXAA AND A NSAID | Cancer Research Technology Limited (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080044-A1 | ANTI-CANCER COMBINATIONS OF DMXAA AND A NSAID | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131059-A1 | Synergistic mixture of 5,6-dimethylxanthenone and diclofenac | ANXA5, ANXA1, ANXA7 | STING1 2530/4885GLA 1437/4885MEN1 1611/4885 |
| US-20090062377-A1 | ANTI-CANCER COMBINATIONS | ANXA5, ANXA1, ANXA7 | STING1 2853/4885GLA 811/4885MEN1 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.